24 September 2015  
EMA/CHMP/631451/2015  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Vidaza 
azacitidine 
On 24 September 2015, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion recommending a change to the terms of the marketing authorisation for the medicinal product 
Vidaza. The marketing authorisation holder for this medicinal product is Celgene Europe Limited. 
The CHMP adopted a new indication as follows: 
"Treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with >30% 
marrow blasts according to the WHO classification.”  
For information, the full indications for Vidaza will be as follows2: 
“Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell 
transplantation (HSCT) with:  
 
 
 
intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International 
Prognostic Scoring System (IPSS), 
chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative 
disorder, 
acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World 
Health Organisation (WHO) classification. 
Vidaza is indicated for the treatment of adult patients aged 65 years or older who are not 
eligible for HSCT with AML with >30% marrow blasts according to the WHO classification.”  
Detailed recommendations for the use of this product will be described in the updated summary of product 
characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), 
and will be available in all official European Union languages after a decision on this change to the marketing 
authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days 
from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
  
 
  
 
 
 
                                               
